Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- MTPC: Sales Up 1.2%, Double-digit Growth in Profits
May 30, 2011
- Asahi Kasei Pharma Obtains Marketing Approval for Flivas in South Korea
May 30, 2011
- DSP: Sales Up 28.1% through Acquisition of Sunovion of US
May 30, 2011
- Eisai's Novel Anticancer Drug Halaven Approved in Switzerland
May 30, 2011
- Shionogi: Net Profits Down 48.2% due to Earthquake, US Restructuring
May 30, 2011
- Ajinomoto, Mochida to Codevelop Fixed Dose CCB + ARB Combination from PIII
May 30, 2011
- Taisho: Operating Profits Up 27% due to Decreases in SGA Expenses
May 30, 2011
- Sales Down 0.5% due to Slump of Existing Products: Ono
May 30, 2011
- Glaucoma Treatments Drive Business: Santen
May 30, 2011
- PIII Clinical Trial of Lu AA21004 for MDD Starts in Japan: Takeda
May 30, 2011
- Otsuka Announces 1st Midterm Management Plan
May 30, 2011
- BI, Eli Lilly Obtain Approval for Linagliptin in US
May 30, 2011
- Takara Bio Aims for Sales of \22.7 Bil. in FY2013
May 30, 2011
- Terumo Starts Domestic Clinical Study of Acetaminophen
May 30, 2011
- Mediceo: Yakkasa Reduction Rate of Just 0.5 Points in FY2010
May 30, 2011
- Sales Up 5.6% for Ethical Drugs in March Following Disaster: Crecon Research & Consulting
May 30, 2011
- Wholesale Business Deteriorating due to War for Market Share: Mr Hamada of Toho HD
May 30, 2011
- Foreign-affiliated Drug Companies Outgrow the Market in Japan
May 23, 2011
- Lurasidone Fails to Show Efficacy in Pan-Asia PIII Study: DSP
May 23, 2011
- Top-4 Wholesalers' Operating Profit Rate Falls Below “Worst-ever”Levels Recorded 2 Years Ago
May 23, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…